Innovative nanobody-targeted nanoplatform delivering manganese contrast agents for MRI visualization of pancreatic islet beta cells
Résumé
In 2021, 537 million people worldwide suffer from diabetes. This chronic disease occurs when the pancreas does not produce enough insulin (type 1 diabetes), or when the body does not properly use the insulin which is produced (type 2 diabetes).[1] The cells involved in insulin production are called beta cells, and when they are defective, this leads to a reduction in the beta cells mass (BCM) contributing to diabetes. [2] It therefore seems important to be able to detect and quantify this BCM. To date, there is no diagnostic tools to monitor BCM qualitatively or quantitatively.